Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
This study is to describe neurocognitive function in patients with relapsing multiple sclerosis (RMS) treated with LEMTRADA® in routine clinical practice as measured by the Multiple Sclerosis Cognitive (MS-COG) composite score. Additional neurocognitive tests will also be administered and reviewed as well as MRI data when available. The study includes a screening period of up to 30 days followed by a baseline visit, month 12 and month 24/EQS visit for a total of four visits.
Who may be Eligible
Patients with relapsing forms of MS aged 25-55 years old who are selected for treatment for treatment with Lemtrada(® and enrolled in the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program in the US are eligible for this study. The decision to treat with LEMTRADA(® will be done prior to and independent of the proposal to enroll in this study. To participate, patients must be able to give signed written informed consent.